Actively Recruiting

Age: 18Years +
All Genders
NCT06856993

Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death

Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2026-04-08

300

Participants Needed

1

Research Sites

314 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Acute coronary syndrome (ACS) is one of the main causes of death. Worldwide, tens of millions of patients are hospitalized for coronary heart disease and ACS every year. ACS may show acute myocardial infarction, unstable angina pectoris, and even induce early arrhythmia, leading to sudden death. Sudden cardiac death (SCD) has a strong correlation with ACS. Data from clinical and autopsy studies and death certificates show that 62-85% of patients with out of hospital SCD have a history of ACS, 10% have other cardiac structural abnormalities, and 5% have no cardiac structural abnormalities. An SCD surveillance study from Ireland concluded that most cases occurred in families, and the successful recovery of SCD was mainly related to ventricular fibrillation with arrhythmia. At present, there are few reports on the clinical and prognosis of ACS in China, and there is no guideline or consensus on the prevention and treatment of ACS patients. Known domestic research results show that the proportion of male, overweight / obese, smokers in young ACS patients is higher than that in the elderly group, while the proportion of patients with hypertension, diabetes and cerebrovascular diseases is less than that of the elderly group. The levels of TC, TG, LDL-C and UA and the proportion of low HDL-C in young ACS patients were higher than those in elderly patients; The diagnosis of STEMI was the highest in the young ACS group, while the diagnosis of unstable angina pectoris was the most common in the elderly ACS group. The clinical manifestations of ACS vary greatly. 3% \~ 5% of patients who exclude ACS only through myocardial markers, clinical blood transfusion and ECG still have myocardial infarction (MI). For the emergency department, early prediction of the risk of SCD in ACS patients and timely and accurate screening of high-risk patients are very important.

CONDITIONS

Official Title

Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • The death event happens suddenly
  • Age 63; 18 years
  • The patient had obvious clinical symptoms 24 hours before treatment
  • Life expectancy exceeds 3 days
  • Proxy of patients signs the informed consent form
  • Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016
Not Eligible

You will not qualify if you...

  • Death caused by accident, such as trauma, poisoning, etc.
  • Death from accidental or intentional overdose
  • Death from asphyxia
  • Death is caused by chronic disease or terminal illness
  • The patient died naturally
  • Has participated in other clinical studies
  • Immediate family members give up continuing treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China, 210008

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death | DecenTrialz